AR097997A1 - Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico - Google Patents
Composición farmaceutica de ibuprofeno y tramadol para uso oftálmicoInfo
- Publication number
- AR097997A1 AR097997A1 ARP140103790A ARP140103790A AR097997A1 AR 097997 A1 AR097997 A1 AR 097997A1 AR P140103790 A ARP140103790 A AR P140103790A AR P140103790 A ARP140103790 A AR P140103790A AR 097997 A1 AR097997 A1 AR 097997A1
- Authority
- AR
- Argentina
- Prior art keywords
- tramadol
- ibuprofen
- pharmaceutical composition
- concentration
- ophthalmic
- Prior art date
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title abstract 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001680 ibuprofen Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960004380 tramadol Drugs 0.000 title abstract 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 abstract 1
- 206010015958 Eye pain Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 229960003107 tramadol hydrochloride Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a una composición farmacéutica de ibuprofeno y tramadol para uso oftálmico. Dicha composición resulta para el tratamiento de la inflamación y/o el dolor ocular asociados a diversas enfermedades o estados patológicos que afectan a la zona ocular. En particular, la composición oftálmica está indicada, por ejemplo, para el tratamiento del dolor y/o la inflamación tras cirugía ocular. Reivindicación 1: Composición farmacéutica oftálmica acuosa que comprende: a) ibuprofeno, o una sal farmacéuticamente aceptable del mismo, en una concentración comprendida entre 0,01% (p/v) y 0,5% (p/v); y b) tramadol, o una sal farmacéuticamente aceptable del mismo, en una concentración, expresada como concentración equivalente de hidrocloruro de tramadol, comprendida entre 0,05% (p/v) y 2% (p/v).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201300963A ES2540151B1 (es) | 2013-10-11 | 2013-10-11 | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097997A1 true AR097997A1 (es) | 2016-04-27 |
Family
ID=51868157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103790A AR097997A1 (es) | 2013-10-11 | 2014-10-10 | Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10292953B2 (es) |
| EP (1) | EP2862565B1 (es) |
| AR (1) | AR097997A1 (es) |
| BR (1) | BR102014025307B1 (es) |
| CY (1) | CY1120642T1 (es) |
| DK (1) | DK2862565T3 (es) |
| ES (2) | ES2540151B1 (es) |
| HR (1) | HRP20181282T1 (es) |
| HU (1) | HUE040093T2 (es) |
| MX (1) | MX355770B (es) |
| PL (1) | PL2862565T3 (es) |
| PT (1) | PT2862565T (es) |
| RU (1) | RU2694369C2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITUB20153104A1 (it) * | 2015-08-13 | 2017-02-13 | Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm | Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti |
| ES2604816B1 (es) * | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
| AR102172A1 (es) | 2015-10-05 | 2017-02-08 | Química Luar S R L | Una composición farmacéutica bactericida y virucida |
| RU2624901C2 (ru) * | 2015-10-05 | 2017-07-07 | Елизавета Геннадьевна Полунина | Средство для аппликационной анестезии с антисептическими, оптикокератопротективными свойствами и способ его применения в офтальмологии |
| CA3038115A1 (en) * | 2016-09-30 | 2018-04-05 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| HUE062529T2 (hu) * | 2019-07-09 | 2023-11-28 | Farmalider Sa | Ibuprofén és tramadol kombinációja fájdalom csillapítására |
| TW202408467A (zh) * | 2022-07-06 | 2024-03-01 | 日商樂敦製藥股份有限公司 | 眼科組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB971700A (en) | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
| US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| GB1497044A (en) | 1974-03-07 | 1978-01-05 | Prodotti Antibiotici Spa | Salts of phenyl-alkanoic acids |
| AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
| TWI347201B (en) * | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| CN1513442A (zh) * | 2003-06-26 | 2004-07-21 | 昆明市延安医院 | 精氨酸-布洛芬混合物的制法和用途 |
| KR20080016621A (ko) * | 2005-06-09 | 2008-02-21 | 바이올리폭스 에이비 | 염증성 질병 치료용 조성물 및 방법 |
| MX2009004203A (es) * | 2006-10-20 | 2009-07-02 | Mcneil Ppc Inc | Combinaciones de paracetamol/ibuprofeno y metodo para su uso. |
| BRPI0810773A2 (pt) * | 2007-04-30 | 2014-10-07 | Adolor Corp | Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição. |
| ES2356762B1 (es) * | 2009-09-04 | 2011-11-24 | Farmalider S.A. | Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma. |
| CN102058581B (zh) * | 2010-11-30 | 2013-01-30 | 广东宏盈科技有限公司 | 一种眼用凝胶 |
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
| ES2423866B1 (es) * | 2012-02-22 | 2014-06-10 | Farmalider, S.A. | Composición farmaceútica de ibuprofeno y tramadol para inyección |
| GB201217522D0 (en) * | 2012-10-01 | 2012-11-14 | Sharma Anant | ophthalmic therapy |
-
2013
- 2013-10-11 ES ES201300963A patent/ES2540151B1/es active Active
-
2014
- 2014-10-08 MX MX2014012158A patent/MX355770B/es active IP Right Grant
- 2014-10-10 US US14/511,321 patent/US10292953B2/en active Active
- 2014-10-10 AR ARP140103790A patent/AR097997A1/es not_active Application Discontinuation
- 2014-10-10 PT PT14380031T patent/PT2862565T/pt unknown
- 2014-10-10 ES ES14380031.6T patent/ES2685023T3/es active Active
- 2014-10-10 EP EP14380031.6A patent/EP2862565B1/en active Active
- 2014-10-10 BR BR102014025307-6A patent/BR102014025307B1/pt active IP Right Grant
- 2014-10-10 HU HUE14380031A patent/HUE040093T2/hu unknown
- 2014-10-10 RU RU2014140885A patent/RU2694369C2/ru active
- 2014-10-10 DK DK14380031.6T patent/DK2862565T3/en active
- 2014-10-10 PL PL14380031T patent/PL2862565T3/pl unknown
-
2018
- 2018-08-03 HR HRP20181282TT patent/HRP20181282T1/hr unknown
- 2018-08-17 CY CY181100867T patent/CY1120642T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2862565B1 (en) | 2018-05-23 |
| PT2862565T (pt) | 2018-10-16 |
| MX2014012158A (es) | 2015-05-27 |
| PL2862565T3 (pl) | 2018-10-31 |
| EP2862565A1 (en) | 2015-04-22 |
| BR102014025307B1 (pt) | 2021-11-03 |
| ES2540151A1 (es) | 2015-07-08 |
| HUE040093T2 (hu) | 2019-02-28 |
| RU2014140885A3 (es) | 2018-06-14 |
| DK2862565T3 (en) | 2018-08-13 |
| MX355770B (es) | 2018-04-30 |
| ES2685023T3 (es) | 2018-10-05 |
| US20150105468A1 (en) | 2015-04-16 |
| HRP20181282T1 (hr) | 2018-10-05 |
| US10292953B2 (en) | 2019-05-21 |
| BR102014025307A2 (pt) | 2015-09-29 |
| RU2694369C2 (ru) | 2019-07-12 |
| RU2014140885A (ru) | 2016-04-27 |
| CY1120642T1 (el) | 2019-12-11 |
| ES2540151B1 (es) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097997A1 (es) | Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| AR121843A2 (es) | Formulación oftálmica y método para mejorar la presbicia | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2012001583A1 (es) | Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección. | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| CO2020016480A2 (es) | Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |